Status:
COMPLETED
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL. Olod...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of chronic obstructive pulmonary disease
- Smoking history of more than 10-pack years
- Exclusion criteria:
- History of asthma, allergic rhinitis, myocardial infarction or unstable of life-threatening cardiac arrhythmias
- Marked baseline prolongation of QT/QTc interval
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01809262
Start Date
December 1 2005
End Date
November 1 2006
Last Update
June 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1222.3.1 Atrium medisch centrum
Heerlen, Netherlands